Ozanimod

TABLE OF CONTENTS

4 OVERVIEW
4 Drug Overview
5 Product Profiles
5 ozanimod : Crohn’s disease
18 ozanimod : Multiple sclerosis (MS)
27 ozanimod : Ulcerative colitis

LIST OF FIGURES
11 Figure 29: Datamonitor Healthcare’s drug assessment summary of etrolizumab in Crohn’s disease
12 Figure 6: Datamonitor Healthcare’s drug assessment summary of filgotinib in Crohn’s disease
20 Figure 23: Datamonitor Healthcare’s drug assessment summary of Stelara in Crohn’s disease
21 Figure 23: Datamonitor Healthcare’s drug assessment summary of Stelara in Crohn’s disease
23 Figure 31: Etrolizumab for Crohn’s disease – SWOT analysis
30 Figure 34: Ozanimod for Crohn’s disease – SWOT analysis
31 Figure 6: Datamonitor Healthcare’s drug assessment summary of ozanimod in Crohn’s disease
32 Figure 27: Tysabri sales for Crohn’s disease in the US, 2016–25

LIST OF TABLES
6 Table 1: Ozanimod drug profile
7 Table 2: Ozanimod Phase III trials in Crohn’s disease
10 Table 3: Ozanimod Phase II data in Crohn’s disease
19 Table 4: Ozanimod drug profile
25 Table 28: Tysabri pivotal trial data in Crohn’s disease
26 Table 6: Ozanimod sales for multiple sclerosis across the US and five major EU markets, by country ($m), 2016–25
28 Table 7: Ozanimod drug profile